{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=10", "query": { "intervention": "Arm 1- Dose Expansion", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 464, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:48:00.086Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04144036", "title": "Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft-versus-host Disease" ], "interventions": [ { "name": "Neihulizumab, 3 mg/kg", "type": "BIOLOGICAL" }, { "name": "Neihulizumab, 6 mg/kg", "type": "DRUG" }, { "name": "Neihulizumab, 9 mg/kg", "type": "DRUG" }, { "name": "Neihulizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sameem M. Abedin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-12-14", "completion_date": "2024-07-07", "has_results": false, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04144036" }, { "nct_id": "NCT01609556", "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2012-06-28", "completion_date": "2018-03-19", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 10, "location_summary": "Fairway, Kansas • Boston, Massachusetts • Detroit, Michigan + 6 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609556" }, { "nct_id": "NCT00948922", "title": "Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2009-06-18", "completion_date": "2019-05-14", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00948922" }, { "nct_id": "NCT04910568", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2021-07-26", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910568" }, { "nct_id": "NCT01207323", "title": "A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Tumors, Malignant" ], "interventions": [ { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-11-09", "completion_date": "2018-04-23", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 3, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207323" }, { "nct_id": "NCT00858377", "title": "A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Solid Tumors", "Tumors" ], "interventions": [ { "name": "Arm 1- Dose Escalation", "type": "DRUG" }, { "name": "Arm 1- Dose Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2009-08-10", "completion_date": "2019-04-03", "has_results": false, "last_update_posted_date": "2019-05-06", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858377" }, { "nct_id": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Oxaliplatin+Capecitabine+Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-01-11", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 7, "location_summary": "Clayton, North Carolina • Durham, North Carolina • Henderson, North Carolina + 4 more", "locations": [ { "city": "Clayton", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342937" }, { "nct_id": "NCT04990739", "title": "Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "MTB-9655", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MetaboMed Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-06-30", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990739" }, { "nct_id": "NCT00960492", "title": "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Giant Cell Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "XL184", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2009-09", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2014-09-22", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 8, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960492" }, { "nct_id": "NCT04730258", "title": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "AML", "MDS", "CMML" ], "interventions": [ { "name": "CFI-400945", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treadwell Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-04-16", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-11-15T11:48:00.086Z", "location_count": 6, "location_summary": "Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730258" } ] }